16/10/2025
Introducing Upadacitinib at Dermatherapie Clinic
Science meets precision.
We’re excited to introduce Upadacitinib, a next-generation selective JAK-1 inhibitor—now available at Dermatherapie Clinic for select dermatology indications.
🧬 Mechanism of Action:
Upadacitinib works by selectively inhibiting the Janus kinase-1 (JAK-1) pathway, a key driver in inflammatory skin diseases like atopic dermatitis, psoriasis, and certain autoimmune conditions.
By targeting JAK-1 specifically, it modulates the release of inflammatory cytokines (IL-4, IL-13, IL-22, IL-31, IFN-γ) that trigger itch, redness, and flare-ups—without broadly suppressing the immune system.
✅ FDA Approved:
• Atopic Dermatitis (2022)
• Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Ulcerative Colitis, Crohn’s Disease
Upadacitinib brings dermatology in line with systemic immunology — a truly cross-disciplinary molecule.
🩺 Why It’s Safer:
Unlike older JAK inhibitors such as Tofacitinib (which blocks multiple JAK pathways), Upadacitinib’s selective JAK-1 inhibition minimizes off-target effects — resulting in fewer adverse events and a superior safety profile.
✨ Results that Matter:
• Faster symptom control
• Greater reduction in itch and inflammation
• Visible skin clearance
• Marked improvement in quality of life scores
💬 In short:
Targeted. Effective. Safe.
A step forward in managing complex inflammatory skin diseases with science-backed precision.
🔬 Now available at Dermatherapie Clinic.
For patients struggling with chronic eczema, dermatitis, or autoimmune flares.
